BioIntervene

Recent Finacing

Series A

Recent Raise

$30M

BioIntervene is a preclinical biopharmaceutical developing selective A3 adenosine receptor agonists, preparing lead BIO-205 for clinical trials in neuropathic, inflammatory and neurodegenerative pain, with exclusively licensed patents.

Founded 2014

California, United States

1-10

Private

biointervene.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Pharmaceutical

Recent Investors

Financials

$30M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at BioIntervene.